NCT05576402

Brief Summary

Inflammatory bowel diseases comprise two distinctive entities: Crohn's disease and ulcerative colitis. During the last decade, endoscopic assessment of inflammation has become relevant since it is a prognostic factor. As a consequence, therapeutic targets now contemplate mucosal healing as part of the goals to be achieved. Endoscopic scores for Crohn's disease and ulcerative colitis have been developed to objectively assess the mucosal inflammatory activity. Although they may have some limitations, these scores have been widely accepted in referral centers, especially since they have been adopted as standard evaluation in inflammatory bowel disease clinical trials . However, their use in the setting of endoscopic practice outside centers with a high volume or with less experience in clinical trials is not known.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 2, 2022

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

October 8, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 12, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2023

Completed
20 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2023

Completed
Last Updated

December 28, 2022

Status Verified

December 1, 2022

Enrollment Period

9 months

First QC Date

October 8, 2022

Last Update Submit

December 26, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Endoscopic score report

    Proportion of colonoscopy reports among inflammatory bowel disease patients which include an endoscopic score to assess inflammatory activity

    January 2018-October 2022

Interventions

colonoscopyPROCEDURE

endoscopic exploration of colonic mucosa to evaluate inflammatory activity in patients with either Crohn's disease or ulcerative colitis

Also known as: endoscopic score assessment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adult patients who have already received a diagnosis of either Crohn's disease or ulcerative colitis

You may qualify if:

  • Adult patients who underwent colonoscopy for the evaluation of mucosal inflammatory activity
  • Patients with an established diagnosis of either Crohn's disease or ulcerative colitis

You may not qualify if:

  • Sigmoidoscopies performed in ulcerative colitis for the assessment of mucosal inflammatory activity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CEMIC

Buenos Aires, 1425, Argentina

RECRUITING

MeSH Terms

Conditions

Inflammatory Bowel Diseases

Interventions

Colonoscopy

Condition Hierarchy (Ancestors)

GastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Endoscopy, GastrointestinalEndoscopy, Digestive SystemDiagnostic Techniques, Digestive SystemDiagnostic Techniques and ProceduresDiagnosisEndoscopyDiagnostic Techniques, SurgicalDigestive System Surgical ProceduresSurgical Procedures, OperativeMinimally Invasive Surgical Procedures

Study Officials

  • Juan S Lasa, MD

    Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Juan S Lasa, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

October 8, 2022

First Posted

October 12, 2022

Study Start

May 2, 2022

Primary Completion

January 31, 2023

Study Completion

February 20, 2023

Last Updated

December 28, 2022

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations